In response to President Obama's FY 2016 budget proposal, BIO's Jim Greenwood cited provisions proposing changes to biologic data exclusivity and cuts to Medicare Part D and B as "deeply troubling" and claimed they would be "detrimental to the development of new cures and treatments for patients in need." Amidst prise for other aspects, Greenwood noted BIO will continue to work with Administration "in pursuit of public policies that encourage investment in biotech innovation."